{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:20:30Z","timestamp":1787062830804,"version":"build-2736575974"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>CD72 is a highly required regulatory molecule in B cells. Its sufficient expression is crucial for maintaining self-tolerance. In contrast, soluble CD72 (sCD72) is reported to be increased in the serum of autoimmune diseases such as systemic lupus erythematosus and primary Sjogren\u2019s syndrome (pSS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      We wanted to assess the biological effect of sCD72 on CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We performed mass spectrometry and co-immunoprecipitation experiments to look for a sCD72 receptor on activated CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells. Afterward, to explore the biological functions of sCD72, we used flow cytometry for the cytokine secretion profile, a phosphorylation assay for the signaling pathway, and a CFSE dye-based assay for cell proliferation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We found and validated the sCD72 and CD6 interaction as a possible ligand-receptor interaction. We also demonstrated that sCD72 significantly increases the expression of pro-inflammatory cytokines, namely IL-17A and IFN-\u03b3, in activated CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells and increases the proliferation of CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells, possibly through its activation of the SLP-76-AKT-mTOR pathway.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The sCD72-CD6 axis on activated CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells is probably a new signaling pathway in the induction of immune-mediated diseases. Therefore, targeting sCD72 may become a valuable therapeutic tool in some autoimmune disorders.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2024.1367120","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:44:36Z","timestamp":1720053876000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Soluble CD72, is a T-cell activator probably via binding to CD6 in homeostasis and autoimmunity"],"prefix":"10.3389","volume":"15","author":[{"given":"Nasren","family":"Eiza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Sabag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofra","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Toubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahava","family":"Vadasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2004.08.002","article-title":"Molecular interactions regulate BCR signal inhibition by CD22 and CD72","volume":"25","author":"Nitschke","year":"2004","journal-title":"Trends Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.160.10.4662","article-title":"The B cell surface protein CD72 recruits the tyrosine phosphatase SHP-1 upon tyrosine phosphorylation","volume":"160","author":"Adachi","year":"1998","journal-title":"J\u00a0Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.4049\/jimmunol.164.3.1223","article-title":"CD72 negatively regulates signaling through the antigen receptor of B cells","volume":"164","author":"Adachi","year":"2000","journal-title":"J Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxh307","article-title":"Requirement for CD100-CD72 interactions in fine-tuning of B-cell antigen receptor signaling and homeostatic maintenance of the B-cell compartment","volume":"17","author":"Kumanogoh","year":"2005","journal-title":"Int Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/08916930601118890","article-title":"Down-regulation of CD72 and increased surface IgG on B cells in patients with lupus nephritis","volume":"40","author":"Nakano","year":"2007","journal-title":"Autoimmunity"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.11.010","article-title":"A regulatory role for CD72 expression on B cells in systemic lupus erythematosus","volume":"43","author":"Vadasz","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20160560","article-title":"CD72 negatively regulates B lymphocyte responses to the lupus-related endogenous toll-like receptor 7 ligand Sm\/RNP","volume":"213","author":"Akatsu","year":"2016","journal-title":"J Exp Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.4110\/in.2019.19.e1","article-title":"CD72 is a negative regulator of B cell responses to nuclear lupus self-antigens and development of systemic lupus erythematosus","volume":"19","author":"Tsubata","year":"2019","journal-title":"Immune Netw"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2016.02.004","article-title":"Increased soluble CD72 in systemic lupus erythematosus is associated with disease activity and lupus nephritis","volume":"164","author":"Vadasz","year":"2016","journal-title":"Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.2004.00187.x","article-title":"Increased expression of the B-cell-regulatory molecule CD72 in primary Sj\u00f6gren\u2019s syndrome","volume":"63","author":"Smith","year":"2004","journal-title":"Tissue Antigens"},{"key":"B11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12865\u2013020-00351\u20132","article-title":"A regulatory role for CD72 expression on B cells and increased soluble CD72 in primary Sjogren\u2019s syndrome","volume":"21","author":"Shen","year":"2020","journal-title":"BMC Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2017.05.006","article-title":"Pathogenesis of human systemic lupus erythematosus: A cellular perspective","volume":"23","author":"Moulton","year":"2017","journal-title":"Trends Mol Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102870","article-title":"Abnormalities of T cells in systemic lupus erythematosus: new insights in pathogenesis and therapeutic strategies","volume":"132","author":"Li","year":"2022","journal-title":"J\u00a0Autoimmun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1074\u20137613(00)00062\u20135","article-title":"Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: A novel mechanism for regulating B cell signaling","volume":"13","author":"Kumanogoh","year":"2000","journal-title":"Immunity"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-022-01674-z","article-title":"The star target in SLE: IL-17","volume":"72","author":"Yi","year":"2023","journal-title":"Inflammation Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1593141","article-title":"The role of IL-17 in SLE and its potential as a therapeutic target","volume":"15","author":"Koga","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.22034\/iji.2020.83264.1617","article-title":"Serum level of soluble lymphocyte-activation gene 3 is increased in patients with rheumatoid arthritis","volume":"17","author":"Saadati","year":"2020","journal-title":"Iran J Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"21319","DOI":"10.1038\/s41598-022-25466-x","article-title":"Soluble immune checkpoint molecules in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"12","author":"Pyo","year":"2022","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cells9122589","article-title":"Soluble CD5 and CD6: lymphocytic class I scavenger receptors as immunotherapeutic agents","volume":"9","author":"Velasco-de Andr\u00e9s","year":"2020","journal-title":"Cells"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2174\/1389450116666150825120536","article-title":"CD6 as a cell surface receptor and as a target for regulating immune\u00a0responses","volume":"17","author":"Brown M","year":"2015","journal-title":"Curr Drug Targets"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20151785","article-title":"CD6 modulates thymocyte selection and peripheral T cell homeostasis","volume":"213","author":"Orta-Mascar\u00f3","year":"2016","journal-title":"J Exp Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jneuroim.2014.08.621","article-title":"ALCAM and CD6 - multiple sclerosis risk factors","volume":"276","author":"Wagner","year":"2014","journal-title":"J\u00a0Neuroimmunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4103\/0972\u20132327.192384","article-title":"CD6 gene polymorphism rs17824933 is associated with multiple sclerosis in Indian population","volume":"19","author":"DCunha","year":"2016","journal-title":"Ann Indian Acad Neurol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1615253114","article-title":"CD6 as a potential target for treating multiple sclerosis","volume":"114","author":"Li","year":"2017","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.143.8.2439","article-title":"Anti-T12, an anti-CD6 monoclonal antibody, can activate human T lymphocytes","volume":"143","author":"Gangemi","year":"1989","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.36.6.777","article-title":"Immunologic responses of progressive multiple sclerosis patients treated with an anti-T-cell monoclonal antibody, anti-T12","volume":"36","author":"Hafler","year":"1986","journal-title":"Neurology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI147334","article-title":"The CD6\/ALCAM pathway promotes lupus nephritis via T cell\u2013mediated responses","volume":"132","author":"Chalmers","year":"2022","journal-title":"J\u00a0Clin Invest"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2010.07.005","article-title":"Aberrant expression of CD6 on B cell subsets from patients with Sjogrens syndrome","volume":"35","author":"Alonso","year":"2010","journal-title":"J\u00a0Autoimmun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/art.41288","article-title":"Attenuation of murine collagen-induced arthritis by targeting CD6","volume":"72","author":"Li","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.autrev.2017.12.004","article-title":"Clinical and experimental evidence for targeting CD6 in immune-based disorders","volume":"17","author":"Consuegra-Fern\u00e1ndez","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B31","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40259\u2013013-0027\u20134","article-title":"CD6 as a therapeutic target in autoimmune diseases: Successes and challenges","volume":"27","author":"Pinto","year":"2013","journal-title":"BioDrugs"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1367120\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:44:40Z","timestamp":1720053880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1367120\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2024.1367120"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1367120","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,4]]},"article-number":"1367120"}}